MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. (MAIA) on November 7, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Chicago, IL. The filing reports on clinical trial updates presented at the Society for Immunotherapy of Cancer (SITC) 2025 conference.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development events and does not contain financial statements or performance metrics.
Material Changes and Clinical Updates
The Company announced the presentation of two clinical trial posters at SITC 2025:
- THIO-104 Poster: Presented on November 7, 2025. Details a Phase 3 study of Ateganosine (THIO) sequenced with Immune Checkpoint Inhibitor (ICI) versus standard of care chemotherapy in ICI-resistant advanced Non-Small Cell Lung Cancer (NSCLC).
- THIO-101 Poster: Scheduled for presentation on November 10, 2025. Details a Phase 2 study of Ateganosine (THIO) in combination with ICI in patients with advanced NSCLC resistant to prior ICI and chemotherapy.
Both posters are filed as exhibits to this report and will be posted on the Company's website.
Guidance, Risks, and Forward-Looking Statements
The filing explicitly states that the THIO-104 and THIO-101 posters contain forward-looking statements. Investors are cautioned not to place undue reliance on these statements. No specific financial guidance or outlook was provided in this document.
Key Facts for Investor Verification
- Verify the full content of the THIO-104 and THIO-101 posters filed as Exhibits 99.1 and 99.2 for specific trial data and timelines.
- Confirm the Company's cash runway and funding status, as this 8-K does not disclose current liquidity or burn rate.
- Monitor the Company's website for the posting of the clinical posters as announced.
- Review the "forward-looking statements" disclaimer within the exhibits to understand the risks associated with the clinical trial projections.